NASDAQ:PGEN Precigen (PGEN) Stock Price, News & Analysis $1.68 +0.02 (+1.20%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.64▼$1.7150-Day Range$1.30▼$1.8852-Week Range$0.84▼$1.93Volume568,749 shsAverage Volume869,802 shsMarket Capitalization$424.07 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Precigen alerts: Email Address Precigen MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside495.2% Upside$10.00 Price TargetShort InterestBearish9.81% of Float Sold ShortDividend StrengthN/ASustainability-0.77Upright™ Environmental ScoreNews Sentiment0.37Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.38) to ($0.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.79 out of 5 starsMedical Sector242nd out of 936 stocksPharmaceutical Preparations Industry108th out of 436 stocks 3.3 Analyst's Opinion Consensus RatingPrecigen has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePrecigen has only been the subject of 4 research reports in the past 90 days.Read more about Precigen's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.81% of the float of Precigen has been sold short.Short Interest Ratio / Days to CoverPrecigen has a short interest ratio ("days to cover") of 15.1, which indicates bearish sentiment.Change versus previous monthShort interest in Precigen has recently decreased by 2.43%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPrecigen does not currently pay a dividend.Dividend GrowthPrecigen does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePrecigen has received a 75.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Precigen is -0.77. Previous Next 2.4 News and Social Media Coverage News SentimentPrecigen has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Precigen this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for PGEN on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows3 people have added Precigen to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Precigen insiders have not sold or bought any company stock.Percentage Held by Insiders44.90% of the stock of Precigen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 33.51% of the stock of Precigen is held by institutions.Read more about Precigen's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Precigen are expected to grow in the coming year, from ($0.38) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precigen is -4.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precigen is -4.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecigen has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Precigen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Precigen Stock (NASDAQ:PGEN)Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Read More PGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PGEN Stock News HeadlinesJuly 23, 2024 | finanznachrichten.dePrecigen, Inc.: Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy LaunchJuly 23, 2024 | prnewswire.comPrecigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy LaunchJuly 27, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.July 21, 2024 | finance.yahoo.comPGEN Aug 2024 2.500 put (PGEN240816P00002500)June 3, 2024 | prnewswire.comPrecigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete ResponseMay 23, 2024 | prnewswire.comPrecigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual MeetingMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Precigen Amid Promising Clinical Data and Strong Financial OutlookMay 15, 2024 | finanznachrichten.dePrecigen, Inc.: Precigen Reports First Quarter 2024 Financial Results and Business UpdatesJuly 27, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Precigen Amid Promising Clinical Developments and Strategic FDA AlignmentMay 14, 2024 | investorplace.comPGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | prnewswire.comPrecigen Reports First Quarter 2024 Financial Results and Business UpdatesMay 14, 2024 | markets.businessinsider.comHere's what to expect from Precigen's earnings reportMay 14, 2024 | msn.comStocks Mixed as US PPI Report Signals Sticky Price PressuresMay 14, 2024 | theglobeandmail.comStock Index Futures Tread Water Ahead of Key U.S. PPI Data and Powell RemarksMay 13, 2024 | msn.comPrecigen Q1 2024 Earnings PreviewMay 8, 2024 | prnewswire.comPrecigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual MeetingApril 26, 2024 | finanznachrichten.deActym Therapeutics Inc.: Actym Therapeutics Appoints Thomas Smart as CEOSee More Headlines Receive PGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PGEN CUSIPN/A CIK1356090 Webwww.precigen.com Phone(301) 556-9900FaxN/AEmployees202Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$14.00 Low Stock Price Target$6.00 Potential Upside/Downside+495.2%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-95,900,000.00 Net Margins-1,781.72% Pretax Margin-1,789.67% Return on Equity-65.36% Return on Assets-50.58% Debt Debt-to-Equity RatioN/A Current Ratio1.72 Quick Ratio1.72 Sales & Book Value Annual Sales$6.22 million Price / Sales68.18 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book3.50Miscellaneous Outstanding Shares252,420,000Free Float139,083,000Market Cap$424.07 million OptionableOptionable Beta1.73 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Randal J. Kirk J.D. (Age 71)Executive Chairman Comp: $100kDr. Helen Sabzevari MPH (Age 61)Ph.D., President, CEO & Director Comp: $1.29MMr. Harry Thomasian Jr. (Age 61)Chief Financial Officer Comp: $524.04kMr. Rutul R. Shah (Age 43)Chief Operating Officer Comp: $393.54kMr. Donald P. Lehr (Age 49)Chief Legal Officer & Corporate Secretary Comp: $652.4kMr. Jeffrey Thomas Perez (Age 52)Senior Vice President of Intellectual Property Affairs Comp: $570.24kMr. Steven HarasymVP & Head of Investor RelationsMr. Rob RussellVP & Head of Human ResourcesDr. Douglas E. Brough Ph.D. (Age 69)Senior VP & Head of Research Dr. Bryan T. Butman Ph.D. (Age 71)Senior VP & Head of CMC More ExecutivesKey CompetitorsCellectisNASDAQ:CLLSLuna InnovationsNASDAQ:LUNABioanalytical SystemsNASDAQ:BASISchrödingerNASDAQ:SDGRSupernus PharmaceuticalsNASDAQ:SUPNView All CompetitorsInsiders & InstitutionsIridian Asset Management LLC CTSold 22,129 shares on 7/26/2024Ownership: 0.820%Bank of New York Mellon CorpBought 19,301 shares on 7/26/2024Ownership: 0.167%Sanders Morris Harris LLCSold 145,500 shares on 7/12/2024Ownership: 0.222%SG Americas Securities LLCSold 20,529 shares on 7/12/2024Ownership: 0.012%Opaleye Management Inc.Sold 65,000 shares on 5/29/2024Ownership: 0.375%View All Insider TransactionsView All Institutional Transactions PGEN Stock Analysis - Frequently Asked Questions How have PGEN shares performed this year? Precigen's stock was trading at $1.34 at the start of the year. Since then, PGEN stock has increased by 25.4% and is now trading at $1.68. View the best growth stocks for 2024 here. How were Precigen's earnings last quarter? Precigen, Inc. (NASDAQ:PGEN) posted its quarterly earnings data on Tuesday, May, 14th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.01. The biotechnology company earned $1.07 million during the quarter, compared to analyst estimates of $1.54 million. Precigen had a negative net margin of 1,781.72% and a negative trailing twelve-month return on equity of 65.36%. Who are Precigen's major shareholders? Top institutional shareholders of Precigen include Iridian Asset Management LLC CT (0.82%), Sanders Morris Harris LLC (0.22%), Bank of New York Mellon Corp (0.17%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Helen Sabzevari, Randal J Kirk, Steven Frank, Jeffrey Thomas Perez, Donald P Lehr, Dean J Mitchell, Jeffrey B Kindler, Harry Jr Thomasian, Rutul R Shah and Trading SA Ares. View institutional ownership trends. How do I buy shares of Precigen? Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Precigen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Precigen investors own include ZIOPHARM Oncology (ZIOP), Nordic American Tankers (NAT), Hess (HES), Boeing (BA), OPKO Health (OPK), Celldex Therapeutics (CLDX) and TherapeuticsMD (TXMD). This page (NASDAQ:PGEN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.